Literature DB >> 30639528

Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification.

Sunisa Chirakul1, Nawarat Somprasong1, Michael H Norris2, Vanaporn Wuthiekanun3, Narisara Chantratita4, Apichai Tuanyok2, Herbert P Schweizer5.   

Abstract

Ceftazidime (CAZ) is the antibiotic of choice for the treatment of Burkholderia pseudomallei infection (melioidosis). The chromosomally-encoded PenA β-lactamase possesses weak cephalosporinase activity. The wild-type penA gene confers clinically significant CAZ resistance only when overexpressed due to a promoter mutation, transcriptional antitermination or by gene duplication and amplification (GDA). Here we characterise a reversible 33-kb GDA event involving wild-type penA in a CAZ-resistant B. pseudomallei clinical isolate from Thailand. We show that duplication arises from exchanges between short (<10 bp) chromosomal sequences, which in this example consist of 4-bp repeats flanked by 3-bp inverted repeats. GDA involving β-lactamases may be a common CAZ resistance mechanism in B. pseudomallei.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amplification; Burkholderia pseudomallei; Ceftazidime; Gene duplication; Resistance; β-Lactamase

Mesh:

Substances:

Year:  2019        PMID: 30639528     DOI: 10.1016/j.ijantimicag.2019.01.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.

Authors:  Marine Schnetterle; Olivier Gorgé; Flora Nolent; Aïda Boughammoura; Véronique Sarilar; Cécile Vigier; Sophie Guillier; Lionel Koch; Nicolas Degand; Vincent Ramisse; Xavier Tichadou; Maria Girleanu; Anne-Laure Favier; Eric Valade; Fabrice Biot; Fabienne Neulat-Ripoll
Journal:  PLoS Negl Trop Dis       Date:  2021-02-16

4.  Antibiotic susceptibility of clinical Burkholderia pseudomallei isolates in northeast Thailand during 2015-2018 and the genomic characterization of β-lactam-resistant isolates.

Authors:  Shirley Hii Yi Fen; Sarunporn Tandhavanant; Rungnapa Phunpang; Peeraya Ekchariyawat; Natnaree Saiprom; Claire Chewapreecha; Rathanin Seng; Ekkachai Thiansukhon; Chumpol Morakot; Narongchai Sangsa; Sunee Chayangsu; Somchai Chuananont; Kittisak Tanwisaid; Wirayut Silakun; Noppol Buasi; Seksan Chaisuksant; Tanin Hompleum; Ploenchan Chetchotisakd; Nicholas P J Day; Wasun Chantratita; Ganjana Lertmemongkolchai; T Eoin West; Narisara Chantratita
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

5.  In silico analyses of penicillin binding proteins in Burkholderia pseudomallei uncovers SNPs with utility for phylogeography, species differentiation, and sequence typing.

Authors:  Heather P McLaughlin; Christopher A Gulvik; David Sue
Journal:  PLoS Negl Trop Dis       Date:  2022-04-13

6.  Optical microscopy reveals the dynamic nature of B. pseudomallei morphology during β-lactam antimicrobial susceptibility testing.

Authors:  Heather P McLaughlin; Julia Bugrysheva; David Sue
Journal:  BMC Microbiol       Date:  2020-07-16       Impact factor: 3.605

7.  Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.

Authors:  Nawarat Somprasong; Carina M Hall; Jessica R Webb; Jason W Sahl; David M Wagner; Paul Keim; Bart J Currie; Herbert P Schweizer
Journal:  mBio       Date:  2020-04-14       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.